These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 30764072)

  • 1. Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus.
    Triplitt C; DeFronzo RA
    Expert Rev Endocrinol Metab; 2006 May; 1(3):329-341. PubMed ID: 30764072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide: incretin therapy for patients with Type 2 diabetes mellitus.
    Tahrani AA; Piya MK; Barnett AH
    Expert Rev Endocrinol Metab; 2008 Nov; 3(6):671-690. PubMed ID: 30764058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide.
    Keating GM
    Drugs; 2005; 65(12):1681-92; discussion 1693-5. PubMed ID: 16060703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide: its position in the treatment of type 2 diabetes.
    Guerci B; Martin CS
    Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2008 Mar; 63(3):158-65. PubMed ID: 18561773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of exenatide as adjunctive therapy in patients with type 2 diabetes.
    Robles GI; Singh-Franco D
    Drug Des Devel Ther; 2009 Sep; 3():219-40. PubMed ID: 19920937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.
    Lam S; See S
    Cardiol Rev; 2006; 14(4):205-11. PubMed ID: 16788334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide: a novel approach for treatment of type 2 diabetes.
    Mikhail N
    South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretins and their role in the management of diabetes.
    Frias JP; Edelman SV
    Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
    Voronova V; Zhudenkov K; Penland RC; Boulton DW; Helmlinger G; Peskov K
    Diabetes Obes Metab; 2018 Aug; 20(8):2034-2038. PubMed ID: 29663628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL
    Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide.
    Bray GM
    Am J Health Syst Pharm; 2006 Mar; 63(5):411-8. PubMed ID: 16484515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
    Cvetković RS; Plosker GL
    Drugs; 2007; 67(6):935-54. PubMed ID: 17428109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.